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Nuclear Exclusion of p33ING1b Tumor
Suppressor Protein: Explored in HCC Cells
Using a New Highly Specific Antibody
Berna Sayan, Neset Cevdet Tolga Emre, Meliha Burcu Irmak,
Mehmet Ozturk, and Rengul Cetin-Atalay
Mouse monoclonal antibodies (MAb) were generated against p33ING1b tumor suppressor protein. 15B9 MAb
was highly specific in recognizing a single protein band of *33 kDa endogenous p33ING1b protein from HCC
cell lines and normal liver tissue by Western blot analysis and by immunoprecipitation. Although p33ING1b
mutations are rarely observed in cancer, differential subcellular distribution and nuclear exclusion of p33ING1b
were reported in different cancer types. Therefore we analyzed the expression and subcellular localization of
p33ING1b in HCC cell lines using 15B9 MAb. So far, p33ING1b mutations or differential subcellular localization
are not reported in HCC. In this study, by indirect immunofluorescence using MAb 15B9, we demonstrate that
nuclear localization of p33ING1b was highly correlated with well-differentiated HCC cell lines whereas poorly
differentiated HCC cells have nuclear exclusion of the protein. Moreover no association was observed between
differential subcellular localization of p33ING1b and p53 mutation status of HCC cell lines. Hence our newly
produced MAb 15B9 can be used for studying cellular activities of p33ING1b under normal and cancerous
conditions.
Introduction
T he ING1b protein is a member of the tumor suppressorgene family involved in cell cycle, apoptosis, and se-
nescence.(1,2) The inhibitor of growth (ING) gene family
comprises the ING1, ING2 ING3, ING4, and ING5 genes,
which carry high homology in-between.(3) Initially, the
p33ING1b gene and then three other alternatively spliced
variants (p47ING1a, p24ING1c, and p27ING1d) of ING1 gene
were discovered.(3,4) It was shown that p33ING1b blocked cell
cycle when ectopically over-expressed in various cell lines.
Expression of the anti-sense construct of p33ING1b also re-
sulted in enhanced transformation.(1) Interaction of p33ING1b
with PCNA upon UV irradiation in addition supports its in-
volvement in apoptosis and DNA repair. Through its PHD
zinc finger motif, the p33ING1b protein was also suggested to
be involved in chromatin remodeling and associated with
histone acetyltransferase activities.(5) The cellular activities of
p33ING1b, along with its nuclear localization signal and PHD
domain motif, strongly indicate that this protein acts in the
nucleus.(6,7) Moreover its interaction with p53 protein depends
on nuclear localization of p33ING1b. Therefore, nuclear local-
ization of p33ING1b is indispensable for its cellular function.
It is well known that tumor suppressor proteins show dif-
ferential expression patterns or mutant products in cancer
tissues. However p33ING1b mutations are rarely observed in
human cancers. In breast, gastric esophageal blood, and brain
tumors, p33ING1b was reported to be down-regulated.(8) On
the other hand, in melanoma, papillary thyroid carcinoma,
and ductal breast carcinoma, increased protein levels in the
cytoplasm was observed.(8) These observations indicate that
the involvement of p33ING1b in carcinogenesis cannot be
explained by only gene mutations or altered expression.
Subcellular targeting of proteins is crucial for their ultimate
function for the cellular machinery. Therefore alterations
in nuclear localization and eventual nuclear exclusion of
p33ING1b protein were previously studied in correlation
with carcinogenesis.(9–11) In this study, we aimed to analyze
subcellular distribution of the p33ING1b protein in HCC
cell lines using our newly produced monoclonal antibodies
(MAb) against the p33ING1b protein. We demonstrated that
p33ING1b protein was mislocalized in HCC cells, which are
poorly differentiated.
Materials and Methods
Expression and purification of GST-p33ING1b
The oligonucleotide primers used for the PCR amplification
of p33ING1b were 50-AGACGTCGACAAATGTTGAGTCCT
GCCAACG-30 (forward) and 50-AGACAAGCTTCTACCTGT
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TGTAAGCCTCTC-30 (reverse). PCRs were performed using
Pfu DNA Polymerase from Stratagene (La Jolla, CA) from
MCF7 cell total cDNA. After cloning, the p33ING1b gene was
verified by sequencing. Protein expression was induced by
the addition of 0.10.2 mM IPTG to actively growing DH5a
cells in LB medium at an A600 of 0.40.5. Incubation was
continued for a further 34 h at 308C; then bacteria were har-
vested by centrifugation. Overexpressed GST-p33ING1b was
purified by batch purification using Glutathione-Sepharose
4B beads equilibrated in the sonication buffer (50 mM Tris-
HCl, 300 mM NaCl, 10% Glycerol (v=v), 7 mM 2-ME [pH 7.8]).
Elution was performed by incubating the bound resin with
5 mM reduced glutathione in 50 mM Tris-HCl (pH8.6), 200
mM KCl, and 7 mM 2-ME for 10 min at room temperature.
Immunization
Purified 80 mg GST-p33ING1b in emulsified Freund’s
complete adjuvant (Sigma Chemical, St. Louis, MO) was sub-
cutaneously injected in 8-week-old female BALB=c mice. Two
boosters of 80mg GST-p33ING1b in incomplete Freund’s
adjuvant at 3-week intervals were applied. Three days be-
fore fusion, intraperitoneal immunization with 60 mg GST-
p33ING1b was carried out.
Cell fusion
Hybridomas were produced by fusing splenocytes of an
immunized BALB=c mouse with SP2 myeloma cells using
PEG 5000 in 1:10 ratio. Cells were grown in RPMI-1640 (Bio-
chrom AG, Berlin, Germany) supplemented with 20% FBS
(v=v), 1x hypoxanthine-aminopterin-thymidine (HAT, Sig-
ma). After 1020 days, supernatants of growing hybridomas
were screened with ELISA against purified GST-p33ING1b
and GST proteins as negative control. Supernatants positive
for GST-p33ING1b but not GST protein were selected then
subcloned by limited serial dilution. Supernatants of the
growing hybridomas were used for further studies.
Tissue culture
Different hepatoma cell lines were used to analyze the cel-
lular properties of p33ING1b with respect to their differenti-
ation status (well-differentiated cells: Huh7, HepG2, Hep3B,
Hep3B-TR; poorly differentiated cells: Mahlavu, PLC=PRF=5,
FOCUS, Sk-Hep1).(13) Cells were grown in DMEM containing
10% fetal calf serum, 1% penicillin=streptomycin, and 1x non-
essential amino acids.
Western blot analysis
Cells or frozen normal liver tissue were lysed by NP-40
lysis buffer (150 mM NaCl, 1.0% NP-40, 50 mM Tris [pH 8.0],
protease inhibitor cocktail-Roche) and centrifuged at
13,000 rpm at 48C for 30 min. Thirty mg protein from each cell
lysate was boiled for 5 min at 908C with Laemmli buffer
(62.5 mM Tris [pH 7.6], 2% SDS, 10% glycerol, BPB, 5% 2-bMe)
and loaded on to 10% polyacrylamide gels. Transfer of the
proteins to PVDF membrane (Millipore, Billerica, MA) was
performed by Bio-Rad semi-dry transfer system (Bio-Rad,
Hercules, CA). Membranes were blocked in TBS-T containing
3% milk powder. Commercial p33ING1b antibody (sc-7566-
goat polyclonal; Santa Cruz Biotechnology, Santa Cruz, CA)
was diluted as recommended by the supplier. Mouse mono-
clonal hybridoma supernatant was diluted 1:1 with TBS-T
containing 3% non-fat milk powder. HRP-conjugated anti-
mouse (P0161, Dako, Glostrup, Denmark) and anti-goat
(P0449, Dako) antibodies were used as the secondary anti-
bodies. Amersham ECL-Plus kit (Amersham Pharmacia Bio-
tech, Uppsala, Sweden) was used for the detection of the
proteins.
Immunoprecipitation
Huh7 cells grown to 70% confluency were then starved in
DMEM lacking methionine (Sigma) and labeled with 200mCi
[35S]Methionine (Amersham) in 4 mL medium for 2 h. Cells
were washed in ice-cold PBS, lysed in NP-40 lysis buffer, and
centrifuged. 200mg protein from Huh7 cell lysate was im-
munoprecipitated with four different p33INGb monoclonal
antibody producing hybridoma supernatants and protein
G-sepharose.
Immunofluorescence
Different hepatoma cells (200,000) were seeded on glass
cover slips in 6-well dishes, then incubated overnight in
Dulbecco’s modified Eagle’s medium with 10% fetal calf se-
rum. Cells were fixed in 100% ice-cold acetone and saturated
for 15 min in PBS-T (0.1%) containing 3% BSA. Anti-p33ING1
15B9 MAb supernatants were diluted at 1:1 in PBS-T and in-
cubated for 1 h. FITC-conjugated goat-anti-mouse (P0479,
Dako) was used as the secondary antibody. Nuclear DNA
was visualized by incubation with 3 mg=mL Hoechst 33258
(Sigma) for 5 min in the dark. Coverslips were then rinsed
with distilled water, mounted on glass microscopic slides, and
examined under fluorescent microscope (Zeiss, Göttingen,
Germany).
Results
Expression and purification of GST-p33ING1b
fusion protein
p33ING1b cDNA was PCR-amplified from the total cDNA
obtained from the MCF7 breast adenocarcinoma cell line.
This cell line was reported to show reduced expression of
p33ING1b, but no mutations were observed.(1) The sequence
of p33ING1b cDNA was confirmed by sequencing. In order to
produce p33ING1 protein, cDNA was subcloned to pGEX-
2TK-P expression vector. Expression and purification of GST-
p33 fusion protein using Gluthatione-Sepharose 4B beads
yielded a total protein amount of *2 mg from 1 L culture
media. Purified GST-p33ING1b was characterized by SDS-
PAGE (Fig. 1). After thrombin digestion, the p33ING1b pro-
tein was observed at the expected molecular weight (Fig. 1,
lane 2).
Production and characterization
of different p33ING1b MAbs
We generated four MAbs against p33ING1b protein from
mice immunized with recombinant GST-p33ING1b protein
by selective ELISA screening of antibody producing hybrid-
omas using GST-p33ING1b. Four hybridoma clones (3G6,
9H9, 20H9, and 15B9) producing MAbs reactive against GST-
fused p33ING1b were selected for further studies. Initially the
MAbs were tested for their ability to recognize recombinant












































GST-p33ING1b protein using Western immunoblotting
technique (Fig. 2).
Characterization of different p33ING1b MAbs
Pure GST protein, GST-p33ING1b fusion protein, and cell
lysate from two different hepatoma cell lines were used to
compare the efficiency of four different hybridoma superna-
tants for the recognition of recombinant versus endogenous
p33ING1b. For that purpose it was important to demonstrate
that these hybridoma supernatants do not cross-react with the
GST tag. Western blotting with 3G6, 9H9, 20H9, and 15B9
revealed that none of these MAbs from hybridoma super-
natants cross-reacted with GST, but they all recognized the
GST-p33ING1b fusion protein very efficiently (Fig. 2A). Sur-
prisingly, only the 15B9 MAb was able to react with endog-
enous p33ING1b protein in two hepatoma cell lines (Fig. 2B),
suggesting that the epitopes of the other three antibodies
might be at the GST-p33ING1b fusion region. Furthermore
when tested by immunoprecipitation, 15B9 was again able to
recognize the endogenous p33ING1b protein (Fig. 2C). In
addition, we checked the reactivity of 15B9 against mouse and
rat tissues by Western blotting. Our results demonstrated that
our newly formed, highly specific antibody raised against
human-p33ING1 recognizes a single band of 33 kDa mouse
and rat p33ING1b protein (data not shown).
Expression of p33ING1b in hepatoma cell lines
Different hepatoma cells were grown in tissue culture.
Proteins were extracted from each cell line and then Western
blot was performed. All the cell lines, with some minor dif-
ferences, expressed p33ING1 protein (Fig. 3A). Similar ex-
pression of p33ING1b in nine hepatoma cell lines and normal
liver were also confirmed by RT-PCR (data not shown). In
addition we analyzed the protein levels in Huh7, HepG2,
Hep3B, and Mahlavu cells compared with calnexin house-
keeping protein. We did not observe significant differential
p33ING1b gene expression in these samples either (Fig. 3B).
Considering cellular functions of p33ING1b and its interac-
FIG. 1. SDS-PAGE analysis of GST-tagged p33ING. GST-
p33ING1 fusion protein (lane 1), thrombin digested GST-
p33ING1 fusion protein (lane 2), and purified GST protein
was loaded to 12% SDS-PAGE and stained with Coomassie-
Briliant Blue. M, molecular weight marker.
FIG. 2. Analysis of different hybridoma supernatants. (A)
Western blotting with 3G6, 9H9, 20H9, and 15B9 hybridoma
supernatants for the recognition of recombinant GST protein
(1) versus GST-p33ING fusion protein (2). (B) Immuno-
precipitation of endogenous p33ING1 protein from meta-
bolically labeled Huh7 hepatoma cells. Protein extracted
from these cells was immunoprecipitated by the four dif-
ferent hybridoma supernatants. Control represents the IP
in which no primary antibody was used. (C) Western blot
analysis of the hybridoma supernatants on endogenous
p33ING1 protein from Huh7 and HepG2 cells.
FIG. 3. Expression of p33ING1 in different hepatoma cell
lines. (A) Thirty mg cell lysate or normal liver extract from
frozen tissue (NL) was loaded to 12% SDS-PAGE and sub-
jected to Western blot analysis with MAb 15B9. (B) Com-
parable p33ING1 protein expression in Huh7, HepG2, Hep3b,
and Mahlavu cells. Blot was reprobed with anti-calnexin
antibodies to confirm equal protein loading in each lane.












































tion with nuclear proteins involved in histone modification,
we then analyzed the subcellular distribution of ING1b on a
set of hepatoma cells with 15B9 antibody by indirect immu-
nofluorescence.
Subcellular distribution of p33ING1b in HCC cell lines
Well-differentiated hepatoma cells—Huh7, HepG2,
Hep3B, Hep3B-TR—and the poorly differentiated cells—
Mahlavu, PLC=PRF=5, FOCUS, Sk-Hep1—were compared in
their p33ING1b subcellular distribution. Huh7, HepG2,
Hep3B-TR cells had nuclear p33ING1b expression, whereas
Hep3B, Mahlavu, PLC=PRF=5, FOCUS, Sk-Hep1 revealed
strong nuclear exclusion of the protein (Fig. 4). The strong
extranuclear staining may indicate cytoplasmic accumulation
of the p33ING1b protein. However we did not observe a
correlation between nuclear localization of p33ING1b and p53
mutations status of these cell lines (Table 1).
Discussion
In this study we generated four MAbs against GST-
p33ING1b protein. MAb 15B9 was the only antibody that
recognized native p33ING1b protein. Western blot analysis
of HCC cell lines Huh7 and HepG2 (Fig. 2) and of mouse
and rat tissues (data not shown) yielded a single protein band
of *33 kDa. Our data indicates that MAb 15B9 is highly
specific to p33INGb isoform since we observed only a single
FIG. 4. Analysis of subcel-
lular distribution of p33ING1
protein detected by immuno-
fluorescence analysis using
MAb 15B9 on a selected set of
cells carrying wild type
(SKHep1 and HepG2), codon
220 mutant (Huh7), codon 249
mutant (Mahlavu and PLC),
and cells without p53 (Hep3B,
Hep3B-TR, and FOCUS).
Nuclear exclusion of p33ING1
protein can be observed
by comparison with nuclear
DNA that was visualized
by Hoechst 33258 counter-
staining. Color images avail-
able online at www
.liebertonline.com=hyb.
Table 1. Subcellular Dstribution of p33ING1 in Relation to p53 Status of Hepatoma Cells
Cell line Differentiation status
p33 nuclear
localization p53 status
HepG2 Well differentiated Nuclear Wild type
Huh7 Well differentiated Nuclear Mutant (Tyr220Cys)
Hep3B-TR Well differentiated Nuclear Null
Hep3B Well differentiated Excluded Null
Sk-Hep1 Poorly differentiated Excluded Wild type
Mahlavu Poorly differentiated Excluded Mutant (Arg249Ser)
PLC=PRF=5 Poorly differentiated Excluded Mutant (Arg249Ser)
FOCUS Poorly differentiated Excluded Null












































protein band from Western blot analysis of Huh7 and HepG2
cells (Fig. 3C). The epitope of the MAb 15B9 must lie on the N-
terminus of the p33ING1b, where there is the least homology
between the p33ING1 isoforms.(3) Therefore MAb 15B9 can be
used as a highly specific antibody for p33ING1b.
Studies on p33ING1 protein showed infrequent mutation
or LOH although it was reported as a putative tumor sup-
pressor.(1) In general tumor suppressor proteins show either
differential expression patterns or an inactive mutant prod-
uct in various types of cancers. p33ING1 down-regulation
was previously reported in breast, gastric, esophageal, blood,
and brain cancers, whereas in melanoma, papillary thyroid
carcinoma and ductal breast carcinoma increased cytoplasmic
protein levels.(8) In addition, p33ING1 was reported to be
mainly localized to the nucleus in most of the normal tis-
sues with the exception of hepatocytes but not bile duct epi-
thelial cells in formalin-fixed sections.(14) Therefore, in this
study using our newly generated highly specific p33ING1b
MAb 15B9, we analyzed p33ING1b differential expres-
sion and eventually its subcellular distribution in HCC cell
lines in correlation with their p53 status. We did not observe
significant differential expression in hepatoma cell lines (Fig.
3A and B). Normal liver tissue from a frozen sample had
similar p33ING1 expression. Previously using different
MAbs, low or no p33ING1 expression was reported with
formalin-fixed liver tissue samples by immunostaining.(14,15)
In our study we did not observe a significant difference in
p33ING1 expression in frozen normal liver tissue when
compared to hepatoma cell lines with Western blot analysis
(Fig. 3A). The comparable expression that we observed in
normal liver tissue may be due to either the use of 15B9 MAb,
which is highly reactive to p33ING1b, or the use of freshly
frozen liver tissue for protein extraction. In addition the
comparable expression of p33ING1b in 15 hepatoma cell lines
and normal liver was also confirmed by RT-PCR. Considering
previous reports about the p33ING1b as putative tumor
suppressor and our results indicating that the involvement of
p33ING1b in cancer cannot be explained by only gene mu-
tations or altered expression, subcellular distribution through
nuclear exclusion of p33ING1b protein may play an impor-
tant role in its cellular activities. Therefore we further ana-
lyzed subcellular distribution of p33ING1b in eight HCC cell
lines. Well-differentiated hepatoma Huh7, HepG2, Hep3B-
TR cells had nuclear p33ING1b and in poorly differentiated
Mahlavu, PLC=PRF=5, FOCUS, Sk-Hep1 cells, p33ING1b was
sequestered in the cytoplasm of the nucleus. Differential dis-
tribution of p33ING1b was independent of p53 status of these
cell lines (Table 1). Our data on the p53 independent differ-
ential subcellular distribution of p33ING1b are in correlation
with previous studies, which also reported p53 independent
activities of p33ING1b in cell proliferation inhibition.(16,17)
ING family proteins have been reported to be involved in
chromatin modeling through their interactions with histone
modifying protein complexes.(19–21) Recent studies on the
histone modification demonstrated the importance of chro-
matin remodeling in gene expression in cancer cells.(22) In-
volvement of p33ING1b in carcinogenesis so far was not fully
explained by mutations or differential expression studies.
However, recently, differential subcellular distribution and
exclusion of p33ING1b were reported in melanoma, acute
lymphoblastic leukemia, invasive breast cancer, and oral
squamous cell carcinomas.(9–12) In this study we report that
poorly differentiated HCC cell lines have nuclear exclusion
of p33ING1. In conclusion these findings indicate that ex-
pulsion of p33ING1b from the nucleus in invasive carcinoma
may explain the molecular involvement of p33ING1b in car-
cinogenesis in support of its previously described function as
tumor suppressor.
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Lane WS, Tan S, Yang XJ, and Côté J: ING tumor suppressor
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